JP2017528117A5 - - Google Patents

Download PDF

Info

Publication number
JP2017528117A5
JP2017528117A5 JP2016575026A JP2016575026A JP2017528117A5 JP 2017528117 A5 JP2017528117 A5 JP 2017528117A5 JP 2016575026 A JP2016575026 A JP 2016575026A JP 2016575026 A JP2016575026 A JP 2016575026A JP 2017528117 A5 JP2017528117 A5 JP 2017528117A5
Authority
JP
Japan
Prior art keywords
antibody molecule
multispecific antibody
molecule according
domain
dsfv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016575026A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017528117A (ja
Filing date
Publication date
Priority claimed from GBGB1411420.1A external-priority patent/GB201411420D0/en
Application filed filed Critical
Publication of JP2017528117A publication Critical patent/JP2017528117A/ja
Publication of JP2017528117A5 publication Critical patent/JP2017528117A5/ja
Pending legal-status Critical Current

Links

JP2016575026A 2014-06-26 2015-06-25 多重特異性抗体コンストラクト Pending JP2017528117A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1411420.1A GB201411420D0 (en) 2014-06-26 2014-06-26 Antibody constructs
GB1411420.1 2014-06-26
PCT/EP2015/064450 WO2015197789A1 (en) 2014-06-26 2015-06-25 Multi-specific antibody constructs

Publications (2)

Publication Number Publication Date
JP2017528117A JP2017528117A (ja) 2017-09-28
JP2017528117A5 true JP2017528117A5 (cg-RX-API-DMAC7.html) 2018-08-02

Family

ID=51410201

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016575026A Pending JP2017528117A (ja) 2014-06-26 2015-06-25 多重特異性抗体コンストラクト

Country Status (10)

Country Link
US (1) US20170198062A1 (cg-RX-API-DMAC7.html)
EP (1) EP3161008B1 (cg-RX-API-DMAC7.html)
JP (1) JP2017528117A (cg-RX-API-DMAC7.html)
CN (1) CN106459217A (cg-RX-API-DMAC7.html)
BR (1) BR112016030424A2 (cg-RX-API-DMAC7.html)
CA (1) CA2953638A1 (cg-RX-API-DMAC7.html)
ES (1) ES2763525T3 (cg-RX-API-DMAC7.html)
GB (1) GB201411420D0 (cg-RX-API-DMAC7.html)
RU (1) RU2710730C2 (cg-RX-API-DMAC7.html)
WO (1) WO2015197789A1 (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108424449A (zh) * 2011-09-16 2018-08-21 Ucb医药有限公司 针对艰难梭菌的主要外毒素TcdA和TcdB的中和抗体
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
GB201412659D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201521393D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521383D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl And Ucb Celltech Method
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
GB201521391D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
BR112019020940A2 (pt) 2017-04-11 2020-05-05 Inhibrx, Inc. construções polipeptídicas multipecíficas que têm ligação a cd3 restrita e métodos de usar as mesmas
CN109970856B (zh) 2017-12-27 2022-08-23 信达生物制药(苏州)有限公司 抗lag-3抗体及其用途
TW201930349A (zh) * 2018-01-08 2019-08-01 大陸商南京傳奇生物科技有限公司 多重特異性抗原結合蛋白及其使用方法
IL323061A (en) 2018-04-11 2025-10-01 Inhibrx Biosciences Inc Multispecific polypeptide constructs with forced CD3 binding and related methods and uses
WO2020023553A1 (en) 2018-07-24 2020-01-30 Inhibrx, Inc. Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
CN113166263A (zh) 2018-10-11 2021-07-23 印希比股份有限公司 Dll3单域抗体及其治疗性组合物
GB201919062D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Antibody
GB201919061D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibody
GB201919058D0 (en) * 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibodies
GB202001447D0 (en) 2020-02-03 2020-03-18 Ucb Biopharma Sprl Antibodies
EP4114373A4 (en) * 2020-03-03 2024-05-01 Systimmune, Inc. Anti-cd19 antibodies and methods of using and making thereof
EP4126936A1 (en) 2020-03-27 2023-02-08 UCB Biopharma SRL Autonomous knob domain peptides
US20240067758A1 (en) 2020-12-07 2024-02-29 UCB Biopharma SRL Multi-specific antibodies and antibody combinations
GB202111905D0 (en) 2021-08-19 2021-10-06 UCB Biopharma SRL Antibodies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2246538C2 (ru) * 1998-05-20 2005-02-20 Чугаи Сейяку Кабусики Кайся Способ и набор для выявления гена, кодирующего мембраносвязанный белок, вектор (варианты)
AR056142A1 (es) * 2005-10-21 2007-09-19 Amgen Inc Metodos para generar el anticuerpo igg monovalente
EP2195341B1 (en) * 2007-09-26 2017-03-22 UCB Biopharma SPRL Dual specificity antibody fusions
AU2009288167B2 (en) * 2008-09-03 2015-10-22 Genentech, Inc. Multispecific antibodies
CN102164960A (zh) * 2008-09-26 2011-08-24 罗氏格黎卡特股份公司 双特异性抗-egfr/抗-igf-1r抗体
CA2766608C (en) * 2009-07-06 2018-06-19 F. Hoffmann-La Roche Ag Bi-specific digoxigenin binding antibodies
WO2012025530A1 (en) * 2010-08-24 2012-03-01 F. Hoffmann-La Roche Ag Bispecific antibodies comprising a disulfide stabilized - fv fragment
EP2543680A1 (en) * 2011-07-07 2013-01-09 Centre National de la Recherche Scientifique Multispecific mutated antibody Fab fragments
EP3517548A1 (en) * 2012-03-13 2019-07-31 NovImmune S.A. Readily isolated bispecific antibodies with native immunoglobulin format

Similar Documents

Publication Publication Date Title
JP2017528117A5 (cg-RX-API-DMAC7.html)
RU2017102312A (ru) Конструкции мультиспецифичных антител
RU2017102193A (ru) Конструкции полиспецифических антител
JP2019506841A5 (cg-RX-API-DMAC7.html)
RU2015129762A (ru) ОДНОЛИНКЕРНЫЕ АНТИТЕЛА FabFv И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
JP2018127467A5 (cg-RX-API-DMAC7.html)
JP2014505463A5 (cg-RX-API-DMAC7.html)
JP2020503891A5 (cg-RX-API-DMAC7.html)
JP2016521688A5 (cg-RX-API-DMAC7.html)
JP2020503001A5 (cg-RX-API-DMAC7.html)
HRP20161656T4 (hr) Sredstva za vezanje na cd33
JP2018527919A5 (cg-RX-API-DMAC7.html)
JP2016502515A5 (cg-RX-API-DMAC7.html)
JP2019534277A5 (cg-RX-API-DMAC7.html)
EA201991099A1 (ru) Антитела против cd73 и их применение
HRP20240719T1 (hr) Kimerna i humanizirana monoklonska protutijela protiv ljudskog ctla4 i njihova upotreba
JP2016529215A5 (cg-RX-API-DMAC7.html)
HRP20220111T1 (hr) Protutijela protiv pd-1
AR103868A1 (es) Anticuerpos anti-cd47 como agentes terapéuticos
JP2017529067A5 (cg-RX-API-DMAC7.html)
EA201590986A1 (ru) Антитела к ceacam5 и их применения
EA201690447A1 (ru) БИСПЕЦИФИЧЕСКИЕ МОНОВАЛЕНТНЫЕ ДИАТЕЛА, КОТОРЫЕ СПОСОБНЫ СВЯЗЫВАТЬСЯ С gpA33 И CD3, И ИХ ПРИМЕНЕНИЯ
FI3525583T3 (fi) Anti-c1s-vasta-aineita ja niiden käyttömenetelmiä
JP2016104790A5 (cg-RX-API-DMAC7.html)
RU2016129894A (ru) Ковалентно связанные конъюгаты хеликар-антитело против хеликара и их применения